HCW Biologics Inc (HCWB) — Titan Protect Analysis

HCWB

HCW Biologics Inc

Healthcare · ·

$1.63

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$12M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.95

Based on estimated future earnings — lower means cheaper

Rev Growth

+129,080.7%

Year-over-year revenue change

Profit Margin

-34.7%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.00

+207% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 1 analysts covering this stock

About HCW Biologics Inc

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The co

https://www.hcwbiologics.com

Country: United States Employees: 35 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.429

Positive but modest risk-adjusted returns

Kelly Fraction

0.0396

Modest edge detected — smaller position warranted

Calmar Ratio

-0.810

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-80.5%

Historical annualised return based on price data

Max Drawdown

-99.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$7.35

78% below the year high

52W Low

$0.25

552% above the year low

Avg Volume

20,310,614

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-8.29

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

114.14

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

99.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

49.5%

Profit from core operations before interest and tax

Free Cash Flow

$-11,422,740

Negative — the business is spending more than it generates

Revenue (TTM)

$7M

Total revenue over the last 12 months

Net Income

$-18,117,820

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$5.00

Target Median

$5.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go